New Report Provides Detailed Data on the U.S. Generic Pharmaceuticals Market
Posted on: Wednesday, 16 May 2007, 12:00 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c56819) has announced the addition of Frost & Sullivan's new report: U.S. Generic Pharmaceuticals Outlook to their offering.
This research service titled U.S. Generic Pharmaceuticals Market Outlook provides a detailed analysis of this market, including competitive structure, market and revenue forecasts, and market share analysis. It also examines the major industry challenges and identifies the most promising opportunities for future market growth.
1. Executive Summary - 1. Executive Summary -- 1. Executive Summary
2. U.S. Generic Pharmaceuticals Market - 1. Market Overview -- 1. Introduction -- 2. Scope and Segmentation -- 3. Research Methodology - 2. Market Dynamics -- 1. Market Engineering Measurements -- 2. Market Trends -- 3. Financial Snapshot - 3. Market Forecasts -- 1. Prescription Forecasts -- 2. Revenue Forecasts - 4. Competitive Landscape -- 1. Competitive Structure -- 2. Pipeline Analysis -- 3. Market Share Analysis - 5. Challenges and Opportunities -- 1. Industry Challenges -- 2. Opportunities
3. Decision Support Databases - 1. Demographic Indicator -- 1. Total Population - 2. Market Indicators -- 1. Government Healthcare Expenditure -- 2. Private Healthcare Expenditure -- 3. Pharmaceutical R&D Expenditure -- 4. Percent Pharmaceutical R&D Expenditure -- 5. Number of Hospitals
List of Figures Chapter 2 Generic Pharmaceuticals Market: ANDA Submission and Approval Statistics (U.S.), 2000-2006 Generic Pharmaceuticals Market: Median ANDA Review Time to Approval (U.S.), 1996-2006 Generic Pharmaceuticals Market: Prescription Forecasts (U.S.), 2003-2013 Generic Pharmaceuticals Market: Revenue Forecasts (U.S.), 2003-2013 Generic Pharmaceuticals Market: Competitive Structure (U.S.), 2006 Generic Pharmaceuticals Market: Pending ANDAs by Major Market Participants (U.S.), 2006 Generic Pharmaceuticals Market: Major Patent Expiries (U.S.), 2007-2010 Generic Pharmaceuticals Market: Mergers and Acquisitions (U.S.), 2000-2007 Generic Pharmaceuticals Market: Revenue Share Trends of Major Market Participants (U.S.), 2004-2006 Generic Pharmaceuticals Market: Prescription Share Trends of Major Market Participants (U.S.), 2004-2006 Generic Pharmaceuticals Market: Top 10 Drugs by Revenues (U.S.), 2005 Generic Pharmaceuticals Market: Top 10 Drugs by Revenues (U.S.), 2006 Generic Pharmaceuticals Market: Impact of Top Industry Challenges (U.S.), 2007-2013 Generic Pharmaceuticals Market: Challenges and Opportunities (U.S.), 2007-2013
Chapter 3 Decision Support Database: Total Population in Million (World), 2002-2012 Decision Support Database: Government Healthcare Expenditure in Billion USD (World), 2002-2012 Decision Support Database: Private Healthcare Expenditure Billion USD (World), 2002-2012 Decision Support Database: Pharmaceutical R&D Expenditure in Million USD (World), 2002-2012 Decision Support Database: Pharmaceutical R&D Expenditure as a Percentage of Pharmaceutical Market (World), 2002-2012 Decision Support Database: Number of Hospitals (World), 2002-2012
For more information visit http://www.researchandmarkets.com/reports/c56819
Source: Business Wire
Related Articles
- US Mid-Sized Business Dial-Up Internet Access Services Expenditures By Size of Business, 2007-2012 Features in-Depth Interviews With Key Decision-Makers
- The Report 'China SBR (Styrene Butadiene Rubber) Market Report, 2008-2009' Provides Important Decision Support to Enterprises and Research Institutions
- St. Joseph Health System Selects EPSi for Financial Performance Management and Decision Support Applications
- Patent Expiry of Blockbuster Drugs and Push for Lower Healthcare Costs Drive Generic Pharmaceuticals Market
- Avega's Alliance Suite Rated Highest for Business Decision Support in KLAS' Mid-Year Report
- Research and Markets: HMO's Pharmaceutical Expenditure Decreased Form 89.5% to Reach 81.3%
- Par Pharmaceutical Receives Final Approval to Market Generic Questran(R) Powder and Questran(R) Light Powder for Oral Suspension
- Research and Markets: Real-Time Decision Support and Risk Management Tool at Your Fingertips
- No Need to Tax the Sick: Clinical Guidelines for Rofecoxib As an Alternative Effective Method to the Copayment Policy in the Advent of Increasing Pharmaceutical Expenditures
 |
 |
User Comments (0)
RSS Feeds